Sangamo BioSciences Inc. (SGMO) Sees Unusually-High Trading Volume
Shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) saw strong trading volume on Thursday . 941,050 shares changed hands during mid-day trading, a decline of 13% from the previous session’s volume of 1,080,424 shares.The stock last traded at $4.21 and had previously closed at $4.13.
A number of analysts have recently issued reports on SGMO shares. Cowen and Company reiterated a “buy” rating on shares of Sangamo BioSciences in a research report on Wednesday, August 10th. Jefferies Group reiterated a “buy” rating on shares of Sangamo BioSciences in a research report on Friday, August 5th. Janney Montgomery Scott downgraded Sangamo BioSciences from a “buy” rating to a “neutral” rating and dropped their price target for the company from $15.00 to $8.00 in a research report on Thursday, August 4th. Zacks Investment Research downgraded Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Finally, Wedbush reiterated an “outperform” rating and set a $30.00 price target on shares of Sangamo BioSciences in a research report on Friday, May 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $15.58.
The stock’s market cap is $295.18 million. The firm’s 50-day moving average price is $5.35 and its 200 day moving average price is $5.89.
Sangamo BioSciences (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.14. The business earned $3.70 million during the quarter, compared to analyst estimates of $5.38 million. The firm’s quarterly revenue was down 56.0% on a year-over-year basis. During the same period last year, the firm posted ($0.17) EPS. Equities analysts anticipate that Sangamo BioSciences Inc. will post ($1.11) earnings per share for the current year.
An institutional investor recently raised its position in Sangamo BioSciences stock. Schwab Charles Investment Management Inc. increased its position in Sangamo BioSciences Inc. (NASDAQ:SGMO) by 25.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 254,000 shares of the biopharmaceutical company’s stock after buying an additional 52,171 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.36% of Sangamo BioSciences worth $2,320,000 at the end of the most recent reporting period.
Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.